FDA Approves OLANZAPINE AND FLUOXETINE — Par Health USA, LLC

# FDA Approves Par Pharmaceutical's Generic Olanzapine and Fluoxetine Combination Par Pharmaceutical's approval of generic olanzapine and fluoxetine (ANDA077742) on November 2, 2012, marks a significant entry into the antidepressant-antipsychotic combination market, potentially enabling the company to capture market share from brand-name competitors while providing patients with more affordable treatment options for treatment-resistant depression. The oral formulation's availability as a generic is expected to reduce healthcare costs and increase accessibility for patients requiring this dual-mechanism therapy.